Clinical Trials Logo

Clinical Trial Summary

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.


Clinical Trial Description

Treatment itself will not be given as part of this trial. The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06024603
Study type Interventional
Source Case Comprehensive Cancer Center
Contact Jorge Manrique-Succar, MD
Phone (954) 659-5000
Email manriqj@ccf.org
Status Recruiting
Phase N/A
Start date November 20, 2023
Completion date November 1, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Completed NCT00530192 - Molecular Profiling Protocol (SCRI-CA-001) Phase 0
Recruiting NCT05852717 - Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT06229340 - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Phase 2
Completed NCT00551850 - A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients Phase 1
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Terminated NCT04092179 - Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Phase 1/Phase 2
Recruiting NCT06184035 - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer Phase 1/Phase 2
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Recruiting NCT05864144 - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03187288 - Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS Phase 1
Terminated NCT01320280 - BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer Phase 2
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT04337580 - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Phase 2
Active, not recruiting NCT04310345 - Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents N/A
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Recruiting NCT05662397 - A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Phase 1/Phase 2